Provention Bio Inc.

The momentum for this stock is not very good. Provention Bio Inc. is not a good value stock. Provention Bio Inc. is not a good growth stock. Provention Bio Inc. is a mediocre stock to choose.
Log in to see more information.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development...

News

Contrasting Provention Bio (NASDAQ:PRVB) & Avalo Therapeutics (NASDAQ:AVTX)
Contrasting Provention Bio (NASDAQ:PRVB) & Avalo Therapeutics (NASDAQ:AVTX)

Ticker Report Provention Bio (NASDAQ:PRVB Get Rating) and Avalo Therapeutics (NASDAQ:AVTX Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations...\n more…

Provention Bio (NASDAQ:PRVB) Reaches New 12-Month High at $24.99
Provention Bio (NASDAQ:PRVB) Reaches New 12-Month High at $24.99

Zolmax Provention Bio, Inc. (NASDAQ:PRVB Get Rating) shares reached a new 52-week high on Wednesday . The stock traded as high as $24.99 and last traded at $24.99, with a volume of 2360526 shares changing hands. The stock had previously closed at $24.23. Wall Street Analysts Forecast Growth Several ...\n more…

Provention Bio (NASDAQ:PRVB) Reaches New 12-Month High at $24.99
Provention Bio (NASDAQ:PRVB) Reaches New 12-Month High at $24.99

Ticker Report Provention Bio, Inc. (NASDAQ:PRVB Get Rating) shares reached a new 52-week high on Wednesday . The stock traded as high as $24.99 and last traded at $24.99, with a volume of 2360526 shares changing hands. The stock had previously closed at $24.23. Wall Street Analysts Forecast Growth Several...\n more…

Sanofi completes Provention Bio acquisition
Sanofi completes Provention Bio acquisition

Seeking Alpha - Healthcare Sanofi (SNY) announced Thursday it completed the acquisition of diabetes drugmaker Provention Bio (PRVB) following a ~$2.9B deal announced in March. Read more here.\n more…

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline
Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

Zacks Investment Research Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.\n\n The market expects Provention Bio, Inc. (PRVB) to deliver a year-over-year decline in earnings on higher revenues ...\n more…

Provention Bio gains after HSR waiting period for Sanofi deal expired
Provention Bio gains after HSR waiting period for Sanofi deal expired

Seeking Alpha - Healthcare Provention Bio (PRVB) rose 3.1% in premarket trading after the HSR antitrust waiting period for the company's sale to Sanofi (SNY) expired\n more…